402 related articles for article (PubMed ID: 23141475)
21. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
Sridharan M; Go RS; Willrich MAV
J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
[TBL] [Abstract][Full Text] [Related]
22. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
[TBL] [Abstract][Full Text] [Related]
23. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
[TBL] [Abstract][Full Text] [Related]
24. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
25. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
26. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
[TBL] [Abstract][Full Text] [Related]
27. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
[TBL] [Abstract][Full Text] [Related]
28. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
Nester CM; Brophy PD
Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
[TBL] [Abstract][Full Text] [Related]
29. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.
Ariceta G; Arrizabalaga B; Aguirre M; Morteruel E; Lopez-Trascasa M
Am J Kidney Dis; 2012 May; 59(5):707-10. PubMed ID: 22196848
[TBL] [Abstract][Full Text] [Related]
30. Eculizumab in atypical hemolytic-uremic syndrome.
Tanimoto T; Oshima Y; Kami M
N Engl J Med; 2013 Oct; 369(14):1378-9. PubMed ID: 24088109
[No Abstract] [Full Text] [Related]
31. Eculizumab in atypical hemolytic-uremic syndrome.
Kistler AD
N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088108
[No Abstract] [Full Text] [Related]
32. Eculizumab in atypical hemolytic-uremic syndrome.
Amadio A; Tejani AM
N Engl J Med; 2013 Oct; 369(14):1378. PubMed ID: 24088107
[No Abstract] [Full Text] [Related]
33. Eculizumab in atypical hemolytic-uremic syndrome.
Ring T
N Engl J Med; 2013 Oct; 369(14):1377-8. PubMed ID: 24088106
[No Abstract] [Full Text] [Related]
34. Eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Loirat C
N Engl J Med; 2013 Oct; 369(14):1379-80. PubMed ID: 24088105
[No Abstract] [Full Text] [Related]
35. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
37. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
Patriquin CJ; Kuo KHM
Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
[TBL] [Abstract][Full Text] [Related]
38. Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.
Reuter S; Heitplatz B; Pavenstädt H; Suwelack B
Transplantation; 2013 Nov; 96(10):e74-6. PubMed ID: 24247905
[No Abstract] [Full Text] [Related]
39. Beneficial effect of eculizumab on thrombotic microangiopathies: another point of view.
Park SJ; Shin JI
Am J Kidney Dis; 2014 Jan; 63(1):166-7. PubMed ID: 24360227
[No Abstract] [Full Text] [Related]
40. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
Belingheri M; Possenti I; Tel F; Paglialonga F; Testa S; Salardi S; Ardissino G
Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
